Cholangiocarcinoma refers to bile duct cancer, which is a malignant tumor derived from bile duct epithelial cells and is divided into intrahepatic and extrahepatic bile duct cancer. The main clinical manifestations of cholangiocarcinoma include jaundice, which occurs in more than 90% of patients with cholangiocarcinoma and tends to deepen gradually, grayish stools, anorexia, fatigue, anemia, skin itching and weight loss in a few patients, but also enlarged gallbladder and liver. The tumor may invade or compress the portal vein, which may cause portal hypertension leading to upper gastrointestinal bleeding, and may show the typical manifestation of cholangitis. Ultrasound is preferred for imaging, which can reveal dilated intrahepatic bile ducts or bile duct masses. Other aspects, 3D spiral CT biliary imaging and magnetic resonance biliopancreatic duct imaging can further clarify the location of bile duct cancer and the surrounding invasion. The treatment of cholangiocarcinoma is mainly surgical. Chemotherapy can be used as an adjuvant treatment for progressive cholangiocarcinoma. For the middle and late stages of jaundice relief, hepatic duct jejunostomy, gallbladder open field anastomosis and biliary stenting can be used to reduce jaundice.